The U.S. Food and Drug Administration announced on May 6, 2026, that it is piloting a new class of shorter, focused screening visits. Additionally, these visits aim to expand the scope of FDA inspection oversight without proportionally increasing the agency’s resource burden. The pilot launched in April 2026 and introduces one-day inspectional assessments as a complement to standard multi-day inspections across several FDA programs.
The FDA is conducting these one-day assessments across multiple inspectorates, including human and animal foods, biologics, medical products, and clinical research programs. The agency selects facilities using risk-based criteria such as product type, prior inspection outcomes, and operational characteristics. For regulated companies, this change signals a broader shift in how the FDA plans to deploy its investigators going forward.
What the Pilot Program Involves
By late April 2026, the FDA had completed approximately 46 one-day assessments. Notably, most confirmed compliance and resulted in No Action Indicated (NAI) outcomes. The agency describes these visits as targeted screening tools. Their purpose is to gather compliance data more efficiently, not to replace comprehensive inspections that higher-risk or more complex operations require.
FDA Commissioner Marty Makary noted that shorter, targeted assessments allow for broader surveillance coverage. Indeed, the agency can assess more facilities and gather critical insights without compromising regulatory rigour. That framing matters. The FDA is not signalling a lighter touch on enforcement. It is signalling a wider net.
Investigators retain full authority to expand the scope or duration of an assessment when warranted. The pilot has already demonstrated this flexibility, with some assessments extending beyond one day when investigators identified significant observations. In other words, a facility selected for a one-day visit should be operationally prepared for a longer, more detailed review.
Risk-Based Selection and Data Gathering
One of the more consequential elements of this program is how the FDA plans to use the data it collects. The agency will use data from these assessments to better target future oversight activities. This includes recurring compliance themes, facility-specific risk scores, and discrepancies between registered and actual operations. As a result, the one-day assessments serve two purposes simultaneously: immediate screening and longer-term risk modelling.
FDA Associate Commissioner for Inspections and Investigations Elizabeth Miller stated that the agency is closely analyzing operational and compliance data from these assessments. That analysis covers trends in outcomes, risk signals, and investigator feedback. The goal is to determine how this approach can enhance the broader inspectional strategy.
Broader Reach for Previously Under-Assessed Facilities
The implications are meaningful for any facility that may previously have fallen below the threshold for a full inspection. Shorter visits, therefore, lower the logistical bar for the FDA. Consequently, it becomes more practical to assess facilities that the agency might not have prioritized under previous resource constraints. Companies that have not seen an inspector in several years should not interpret that history as a sign of low priority.
Scope of the Pilot and Next Steps
The pilot will continue through fiscal year 2026, with additional assessments planned across inspectorates. Furthermore, the FDA is developing evaluation metrics to assess effectiveness. These metrics will cover inspection duration, escalation rates, and the utility of findings in informing risk-based decision-making.
The program currently spans a broad product scope: human and animal foods, biologics, medical devices and other medical products, and clinical research sites. Notably, dietary supplement facilities, drug manufacturing sites, and food establishments all fall within categories the pilot already includes.
Importantly, the FDA has confirmed that this initiative does not represent a change in enforcement policy. The one-day format is additive, not substitutive. Higher-risk or more complex facilities that require comprehensive inspectional coverage are not affected by this pilot. Standard inspections remain the primary mechanism for those operations.
What This Means for Your Business
The practical effect of this pilot is that more facilities may receive an FDA visit in 2026 and beyond. Notably, this is a shift from previous resource allocation patterns. Companies that have not been inspected recently, or at all, should not interpret that history as a signal of low priority. The FDA is explicitly designing this program to reach facilities that have not been assessed recently. Critically, the agency is doing so with less advance resource commitment on its side.
For companies operating in any of the affected sectors, internal readiness matters more now, not less. Specifically, that includes dietary supplements, food manufacturing, biologics, medical devices, and clinical research. A one-day assessment is shorter than a standard inspection. Yet it still requires that your facility’s records, procedures, and operations reflect your registered activities. The FDA is specifically tracking discrepancies between registered and actual operations through these visits.
Companies with prior observations are among those the FDA’s risk-based selection criteria would logically prioritize. The same also applies to facilities that have recently changed operations, product lines, or ownership.
Frequently Asked Questions
Are one-day FDA inspections less rigorous than standard inspections?
This is a common point of confusion worth addressing directly. One-day assessments are targeted screening visits, not abbreviated versions of comprehensive inspections. Their scope may be narrower on any given visit. However, investigators retain full authority under existing regulatory frameworks to expand the scope or duration if they observe issues. A facility that receives a one-day visit and has compliance gaps should expect that visit to extend. In some cases, it may escalate to a standard inspection or enforcement action.
Which types of facilities are being selected for these one-day assessments?
The FDA is using risk-based selection criteria that factor in product type, prior inspection history, and operational characteristics. The pilot spans human and animal foods, biologics, medical products, and clinical research programs. That scope is broad enough to include dietary supplement manufacturers, food processing facilities, drug establishments, medical device manufacturers, and clinical trial sites. Facilities with no recent inspection history are not excluded from selection.
Does this pilot change how the FDA will conduct standard inspections going forward?
The one-day assessments are not replacing standard FDA regulatory inspections. The agency has stated clearly that this program does not represent a change in enforcement policy. What it does represent is an expansion of surveillance capacity. Data gathered through these shorter visits will feed into the FDA’s risk models. In turn, those models will inform decisions about which facilities receive more comprehensive inspectional attention in future cycles. Companies should treat this pilot as evidence of a widening regulatory reach. It is not a signal that inspection standards are softening.
Key Takeaways
- The FDA launched a one-day inspectional assessment pilot in April 2026, spanning human and animal foods, biologics, medical products, and clinical research programs.
- The agency completed approximately 46 assessments by late April 2026. Most resulted in NAI outcomes, though some visits extended beyond one day when observations warranted.
- The FDA selects facilities based on risk criteria including product type, prior inspection outcomes, and operational characteristics.
- Data from these visits will feed into more targeted risk models for future FDA inspections, effectively expanding the agency’s surveillance footprint.
- The pilot does not replace standard inspections and does not change enforcement policy, but more facilities may be assessed in the coming months.
Preparing Before a Visit Arrives
Overall, the FDA’s one-day inspectional assessment pilot reflects a clear direction. The agency is extending its compliance oversight to a broader range of facilities. It is doing so without a proportional increase in inspection time per facility. For health and consumer product companies, that means the practical risk of receiving an unannounced or minimally-announced assessment has increased across multiple sectors.
The most effective time to address documentation gaps, procedural inconsistencies, or registration discrepancies is before a visit, not during one. Quality Smart Solutions works with dietary supplement manufacturers, food companies, medical device firms, and other regulated businesses to assess their FDA compliance readiness. To discuss your facility’s current posture, speak with a regulatory specialist at Quality Smart Solutions.
For the full details of the FDA’s announcement, the agency’s official press release on the one-day inspectional assessment pilot is available on FDA.gov.
